Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
信达生物制药宣布一款曾获武田巨额合作的抗体药物偶联物Ⅲ期临床试验成功

Innovent Biologics’ ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps.
信达生物制药的一款抗体药物偶联物候选药物在晚期胃癌的Ⅲ期临床试验中取得成功，目前正在manbetx3.0 接受优先审评，但具体结果细节尚未对外披露。